drugset / Trial / NCT06054932
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-labeled, single-center phase I study in patients with incurable advanced solid tumors, who failed with all previous standard therapy. The aim is to observe and evaluate the safety, tolerability, and immunogenicity of LK101 injection.
Timeline
- Start
- 2023-09-05
- Primary completion
- 2025-12-30
- Completion
- 2026-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LK101 | Vaccine | — | — |